Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently completed a clinical study titled ‘A ...
This unique 3 day course is designed to integrate the key elements of tablet development with hands-on, practical experience in a small scale, lab scale test facility. Each day will consist of ...
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the ...
BASEL, Switzerland, June 25, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s new tablet formulation of CALQUENCE ® (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic ...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
New formulation provides patients with a simplified dosing experience—reducing pill burden and enhancing ease of administration—while preserving flexible dosing options SAN CARLOS, Calif., June 11, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback